David S. Sebag never dreamed that taking the heartburn medication Zantac would eventually lead do being diagnosed with bladder cancer, but that is exactly what happened. Now the Florida man has filed a complaint in the U.S. District Court for the Southern District of Florida, charging multiple drug manufacturers with failing to warn of the dangers posed by the popular drug.
In recent weeks, there’s been a tsunami of lawsuits filed against the manufacturers of Zantac and other heartburn drugs containing ranitidine, holding them responsible for their Zantac cancer diagnosis. At the heart of the various complaints is a chemical called N-Nitrosodimethylamine, or NDMA. Victims are saying that NDMA is found in the medication at dangerously high levels and that the manufacturers were aware of its risks but failed to provide consumers with warnings. Let’s take a look at what N-Nitrosodimethylamine is, and why it is so dangerous.
Two years after losing his mother to breast cancer, an Indiana man has filed a wrongful death lawsuit against several Zantac and generic Zantac manufacturers, blaming them for her illness. Guy Tedesco filed the Zantac cancer lawsuit in the U.S. District Court for the Southern District of Florida on May 12th, seeking damages for himself and for his mother, Teresa. According to the claim, Mrs. Tedesco had taken the heartburn medications for over three decades.
Several months ago, the U.S. Food and Drug Administration reported having found traces of a cancer-causing chemical called N-Nitrosodimethylamine , or NDMA, in the popular heartburn medication ranitidine. Ranitidine in the form of Zantac is one of the top-selling drugs in the world, and though the report raised concerns about Zantac cancer, most people continued taking the medication.
Zantac is one of the most popular medications available. Over the last 15 years, the prescription version of the medication has consistently ranked among the top 60 medications prescribed. In 1988 it became the world’s top-selling drug, and it was the first drug to reach over $1 billion in annual sales. But in recent days Zantac’s active ingredient, ranitidine, has been determined to contain high levels of a dangerous carcinogen, the chemical NDMA. Since then the U.S. Food and Drug Administration has requested that the drug be removed from store shelves, and most major retailers have complied.
Though there is a tremendous national interest in the litigation surrounding Zantac cancer, forward movement on the case has been significantly stymied by the COVID-19 crisis. In a March 20th notice that went out from United States District Court, S.D. Florida to hundreds of plaintiffs, their legal counsel, and defense attorneys alike, the court reviewed and updated the status of the case and how its schedule had been impacted. The case involves Zantac and its generic version ranitidine, which has been cited in product liability litigation accusing the manufacturers and designers of selling a product that it knew could cause cancer, without providing appropriate protections or warnings.
Being diagnosed with cancer has long been one of the top fears for people all around the world. In response people have made significant lifestyle changes: they’ve taken up exercise, lost weight, given up smoking, and adopted healthier diets. Now that the FDA has indicated a cancer risk from long-term use of Zantac or any of its generic versions, many are now giving up the popular heartburn drug, even if they had been taking it based upon their physician’s recommendations or a prescription.
If you’re a regular user of any of the heartburn medications that contain ranitidine, you’re likely closely watching the news for information about Zantac cancer risks. The FDA recently requested the removal of both over-the-counter and prescription versions of ranitidine, which is sold under the brand name Zantac and under several other brands as a generic. The request follows the initial discovery of a contaminant known as N-nitrosodimethylamine (or NDMA) by an independent laboratory, and then again in tests conducted by the agency itself.
Robert R. Pagniello has spent over $600,000 fighting stage 3 colon cancer that he blames on his five-year use of heartburn drug Zantac. He has filed a federal lawsuit against its makers, Sanofi-Aventis US LLC and Beohringer Ingelheim Pharmaceuticals as part of a proposed class action.
With the Food and Drug Administration’s recent announcement that the popular medication Zantac poses a potential cancer risk, many physicians are suggesting that pregnant women find another form of relief for the heartburn discomfort that so frequently accompanies pregnancy. The agency’s testing determined that the medication contains levels of a chemical called NDMA, and that discovery is causing enough concern for popular retailers including Rite Aid, CVS and Walgreens to stop selling it entirely.
Danziger & De Llano, LLP. Office Locations: (Principal Office) Houston, Texas . Contact Danziger & De Llano for more information. Prior results do not guarentee or predict a similar outcome with respect to any future matter.